Septerna, Inc. Common Stock - Asset Resilience Ratio
Septerna, Inc. Common Stock (SEPN) has an Asset Resilience Ratio of 25.44% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check SEPN strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2023–2024)
This chart shows how Septerna, Inc. Common Stock's Asset Resilience Ratio has changed over time. See SEPN equity financing ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Septerna, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Septerna, Inc. Common Stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $154.36 Million | 25.44% |
| Total Liquid Assets | $154.36 Million | 25.44% |
Asset Resilience Insights
- Very High Liquidity: Septerna, Inc. Common Stock maintains exceptional liquid asset reserves at 25.44% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Septerna, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Septerna, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC |
Biotechnology | -55.36% |
|
Krystal Biotech Inc
NASDAQ:KRYS |
Biotechnology | 23.06% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Septerna, Inc. Common Stock (2023–2024)
The table below shows the annual Asset Resilience Ratio data for Septerna, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 24.69% | $112.73 Million | $456.55 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $130.87 Million | -- |
About Septerna, Inc. Common Stock
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 … Read more